Rafael Amado

Scientific Advisor at ReCode Therapeutics

Dr. Amado serves as president, head of global oncology research and development at Zai Labs. He most recently served as executive vice president of research and development at Allogene Therapeutics, Inc., and previously, president of research and development at Adaptimmune Therapeutics PLC, after serving as its chief medical officer. He has held several roles of increasing responsibility at GSK, most recently as senior vice president and head of oncology research and development. Dr. Amado has built a career leading the development of a number of breakthrough therapies in hematology and oncology, with a focus on immunotherapies and CAR-T drug discovery and development.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


ReCode Therapeutics

1 followers

ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases.


Industries

Employees

51-200

Links